Physician profile
Mitchell Alan Peterson
NPI 1629489596
$1,684.38
in general payments reported to CMS, 2019-2025
21 companies · $261 in 2025
The $261 reported for 2025 was more than what 81% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $106 · 2021: $328 · 2022: $182 · 2023: $167 · 2024: $409 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $251.26 | 2019-2023 | |
| Tris Pharma INC | $241.54 | 2019-2025 | Dyanavel Xr, Onyda Xr, Quillichew Er |
| Corium, LLC | $196.18 | 2022-2025 | Azstarys |
| Cranial Technologies, INC | $160.59 | 2019-2024 | Doc Band |
| Ironshore Pharmaceuticals INC. | $160.15 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $154.63 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Supernus Pharmaceuticals, INC. | $105.95 | 2021-2025 | Qelbree |
| Adlon Therapeutics L.P. | $72.46 | 2021 | |
| Collegium Pharmaceutical, INC. | $61.84 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $54.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.85 | 2021 | |
| Kyowa Kirin, INC. | $27.14 | 2025 | |
| Biomarin Pharmaceutical INC. | $25.37 | 2023 | Voxzogo 1.2mg |
| Sanofi Pasteur INC. | $20.76 | 2021 | |
| Organon LLC | $16.81 | 2025 | Nexplanon |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $15.62 | 2019 | |
| Genentech USA, INC. | $15.22 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.90 | 2025 | Zoryve |
| Dermira, INC. | $14.22 | 2019 | |
| Kaleo, INC. | $13.20 | 2023 | Auvi-Q |
| Verrica Pharmaceuticals INC. | $13.15 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.